N@N

NeuroInvestment: Migraine Therapeutics Reviewed by NeuroInvestment

^{Published on 2009-03-02 11:02:38, Last Modified on 2009-03-02 11:03:21 - Market Wire}
 

CARDIFF, CA--(Marketwire - March 2, 2009) - NI Research has released the March issue of NeuroInvestment, which reviews the status and prospects of migraine therapeutics. Triptans are successful, but far from perfect in terms of rapidity and duration of effect, and the cardiovascular side effect profile. The next generation of migraine therapeutics involves two main categories: alternative delivery methods, primarily for rapid migraine relief, and novel mechanisms of action.

Among the companies developing alternative delivery methods are Alexza Pharmaceuticals (NASDAQ: [ ALXA ]), NuPathe, MAP, and Zogenix. Novel mechanism of action drugs reviewed include CGRP-antagonists from Merck and Boehringer-Ingelheim; mGluR5 antagonists from Addex Pharmaceuticals, AMPA/kainate antagonists from Torrey Pines Therapeutics (NASDAQ: [ TPTX ]); NOS inhibitors from NeurAxon; and a 5HT-1f drug from CoLucid.

The March issue of NeuroInvestment also assesses Lundbeck's acquisition of Ovation Pharmaceuticals; the safety questions that remain unresolved regarding neural stem cell implantation; and evaluates Accera, which has just launched Axona as a 'medical food' for Alzheimer's.

About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year subscription is $1700, email or hardcopy. Add $250 for dual delivery, add $50 for airmail delivery outside North America. A three-month trial subscription is $500.

A $1200 introductory rate for new subscribers only is currently being offered for subscription orders placed before April 1.

A recent sample issue of NeuroInvestment is available for download at: [ http://www.neuroinvestment.com/NewNeuroInvestment.html ].

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003; and CNS Disorders/Therapeutics, an annual compendium of all neuro-oriented R&D programs, since 2007.

NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies, and offers M&A/licensing consultation and custom research for large and small pharmaceutical firms.